Trial Profile

Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Depoxythilone (Primary) ; Capecitabine
Indications Advanced breast cancer
Focus Registrational; Therapeutic Use
Sponsors Beijing Biostar Technologies

Most Recent Events

11 Nov 2020 Final overall survival (OS) analysis and updates of other endpoints; results published in the Annals of Oncology
14 Dec 2019 Results (n=54) assessing efficacy of utidelone plus capecitabine presented at the 42nd Annual San Antonio Breast Cancer Symposium
31 Jul 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com